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Abstract
Background: Xiao-Ke-An (XKA) is a Chinese medicine widely used for treating type 2 diabetes mellitus (T2D).
It is composed of eight herbal medicines traditionally used for T2D, including Rehmannia glutinosa Libosch,
Anemarrhena asphodeloides Bunge, Coptis chinensis Franch, etc. The aim of the present study was to investigate
the antidiabetic effects of XKA with both conventional and holistic omics approaches.
Methods: The antidiabetic effect of XKA was first investigated in 3T3-L1 cells to study the effect of XKA on
adipogenesis in vitro. Oil Red O staining was performed to determine the lipid accumulation. The intracellular total
cholesterol (TC) and triglyceride (TG) contents in XKA treated 3T3-L1 cells were also evaluated. The therapeutic
effects of XKA was further evaluated in KKAy mice with both conventional and holistic omics approaches. Body
weight, fasting and non-fasting blood glucose, and oral glucose tolerance were measured during the experiment.
At the time of sacrifice, serum was collected for the measurement of TG, TC, high-density lipoprotein cholesterol
(HDL-c) and low-density lipoprotein cholesterol (LDL-c). The liver, kidney, spleen, pancreas, heart and adipose tissues
were harvested and weighted. The liver was used for further microarray experiment. Omics approaches were
adopted to evaluate the holistic rebalancing effect of XKA at molecular network level.
Results: XKA significantly inhibited adipogenic differentiation, lowered the intracellular TC and TG contents in
3T3-L1 cells. XKA improved the glucose homeostasis and lipid metabolism, ameliorated insulin resistance in
KKAy mice. Futhermore, XKA also exhibited effective therapeutic effects by reversing the molecualr T2D disease
network from an unbalanced state.
Conclusions: This study investigated the antidiabetic effects of XKA with both conventional and holistic omics
approaches, providing both phenotypic evidence and underlying action mechanisms for the clinical use of XKA
treating T2D.
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Background
Type 2 diabetes mellitus (T2D) is one of the fastest
growing public health problems throughout the world
affecting more than 366 million individuals globally [1].
Various antidiabetic medications are clinically available, in-
cluding biguanides, thiazolidinediones, sulfonylureas, alpha-
glucosidase inhibitors, incretin mimetics and enhancers,
insulin [2]. These drugs treat T2D through different mecha-
nisms such as reducing intestinal glucose absorption, lower-
ing hepatic glucose output, enhancing pancreatic insulin
secretion, improving insulin sensitivity and reversing per-
ipheral glucose utilization [2]. Considering the complex
mechanisms and pathophysiological abnormalities in
T2D, it is extremely hard to reverse T2D disease state with
monotherapies [3–5]. Thus combination therapy is be-
coming a promising alternative choice in clinical practice
by designing drug combinations or compound drugs to
interact with multiple targets and achieve synergistic
treatment effects [6]. For example, traditional Chinese
medicines (TCM) are attracting more attentions for
their efficacy and less frequent side effects for treating
T2D [7–10].
A number of antidiabetic efficacy indexes have been
developed for T2D therapy, including body mass index
(BMI), plasma glucose, total cholesterol (TC), triglycer-
ide (TG), high-density lipoprotein cholesterol (HDL-c),
insulin, glycated haemoglobin (HbA1c), etc [11]. How-
ever, most of these indexes only reflect a single aspect
of the antidiabetic effects and could not reflect the
comprehensive impacts caused by the compound drugs.
A combination of markers might perform better than
a single one [12]. Network pharmacology offers a
molecular network view to understand the relation-
ship between drugs and targets, providing a global
perspective to investigate the drug efficacy [13]. Inte-
grating network pharmacology analysis and ‘omics’
data enables the evaluation of the drug efficacy at the
systems network level.
Xiao-Ke-An (XKA) is a traditional Chinese medicine for
‘Xiaoke’ symptom (the description of T2D in TCM), which
was approved by the China Food and Drug Administration.
In previous studies, XKA has been reported to alleviate
hyperglycemia and hyperlipemia [14]. A more compre-
hensive evaluation of the pharmacological effects of
XKA in T2D is needed for better understanding of its
therapeutic effectiveness and action mechanisms. The
3T3-L1 cell is a well characterized cell line for investi-
gating adipocyte differentiation and lipid accumulation,
and KKAy mice is an excellent animal model of T2D,
characterized by obesity, hyperglycaemia, dyslipidaemia,
and insulin resistance. In this study, XKA was investi-
gated for its therapeutic effects in 3T3-L1 cells and




XKA includes Rehmanniae radix, Anemarrhenae
rhizome, Coptidis rhizome, Lycii cortex, Lycii fructus,
Polygonati odorati rhizome, Ginseng radix et rhizoma
and Salviae miltiorrhizae radix et rhizome, with a
6:5:2:4:2:3:2:3 weight ratio of the eight herbal compo-
sitions. XKA was manufactured by Jilin Tonghua
Huaxia Pharmaceutical Co. Ltd. (Jilin, China). Briefly,
the Ginseng radix et rhizome and half of the Anemar-
rhenae rhizome were crushed into powder. Coptidis
rhizome was extracted with water. The remaining half
of the Anemarrhenae rhizome and the five other herbs
were extracted with water together. Both extracts were
concentrated together to syrup. Finally the powder
was mixed to the syrup and dried.
Metformin was purchased from Melone Biotechnology
Co. Ltd. (Dalian, China). Dexamethasone, 3-isobutyl-1-
methylxanthine, dimethyl sulfoxide (DMSO), insulin, Oil
Red O and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) were purchased from Sigma-
Aldrich Co. (USA). Dulbecco's Modified Eagle Medium
(DMEM), bovine serum, fetal bovine serum (FBS),
penicillin and streptomycin were purchased from
Gibco (USA). Triglycerides kit and total cholesterol
kit were purchased from BHKT Clinical Reagent Co.,
Ltd. (Beijing, China). BCA protein assay kit was
purchased from Beyotime Institute of Biotechnology
(Jiangsu, China).
Preparation of XKA extracts
XKA was extracted twice with 70 % ethanol/H2O (1:10,
w/v) for 1 h each time, and then concentrated in vacuum
to obtain the extracts of XKA. The extracts of XKA were
dissolved in DMSO with the final DMSO concentration
less than 0.1 % for this in vitro experiments, and the same
vehicle was used in the control group.
3T3-L1 cell culture
3T3-L1 preadipocytes were obtained from the Cell Bank
of Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China) and cultured in DMEM con-
taining 10 % bovine serum and penicillin/streptomycin
in a humidified atmosphere of 5 % CO2 at 37 °C.
Cell viability assay
Cell viability was determined by MTT assay. The 3T3-
L1 preadipocytes were seeded at 3 × 103 cells/well in
96-well plates and incubated at 37 °C. After 2-day
incubation, the cells were treated with different concentra-
tions of XKA extracts or vehicle for 48 h. At the end,
the medium was removed, and 100 μL of MTT solution
(0.5 mg/mL) was added to the 3T3-L1 cells. After the
wells were incubated for another 4 h at 37 °C, the
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medium was removed, and the synthesized formazan
crystals were dissolved in 100 μL of DMSO. Finally,
absorbance was measured at 580 nm using an infinite
F200 microplate reader instrument (Tecan Group Ltd.,
Switzerland) (n = 3). Data was calculated as a percent-
age of MTT compared to control cells.
3T3-L1 cell differentiation and Oil Red O staining
The 3T3-L1 preadipocytes were induced to differentiate
into adipocytes as described previously [15]. Briefly, the
3T3-L1 preadipocytes were seeded at 1 × 104 cells/well in
48-well plates and proliferated to confluence. Adipogenesis
was triggered with differentiation induction medium con-
taining 0.5 mM 3-isobutyl-1-methylxanthine, 1.0 μM dexa-
methasone and 10 μg/mL insulin in DMEM with 10 %
FBS. Three days later, cells were maintained in a differenti-
ation maintenance medium containing 10 μg/mL insulin in
DMEM with 10 % FBS for another 3 days. Next, the
medium was replaced with DMEM containing 10 % FBS
every 3 days. After 9–11 days’ incubation, more than 80 %
cells were differentiated into adipocytes. Cells were treated
with different concentrations of XKA extracts throughout
the entire differentiation process. The 3T3-L1 adipocytes
were fixed with 0.4 % paraformaldehyde (PFA) for 1 h.
Then the cells were stained with Oil Red O solution for
0.5 h. The cells were washed with 70 % ethanol/H2O (v/v)
twice. Appearance was recorded by an inverted fluores-
cence microscope Leica DMI 6000 B (Leica Microsystems,
Wetzlar, Germany). Then, Oil Red O dye in lipid droplets
was eluted into isopropanol. Finally, absorbance was
measured at 492 nm using an infinite F200 microplate
reader instrument (Tecan Group Ltd., Switzerland) (n = 3).
TG and TC assay in 3T3-L1 cells
The process of differentiating 3T3-L1 preadipocytes into
adipocytes were similar as mentioned previously. Briefly,
Fig. 1 Framework of evaluating the antidiabetic effects of XKA with both conventional and holistic omics approaches
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the 3T3-L1 preadipocytes were seeded at 2 × 104 cells/well
in 24-well plates and proliferated to confluence, and the
differentiation medium was replaced every 2 days.
When more than 80 % cells were differentiated into
adipocytes, cells were washed with phosphate buffer.
The amount of intracellular triglyceride and total chol-
esterol was determined with the triglycerides kit and
total cholesterol kit after cell fractured, respectively.
TG and TC values were corrected by their protein
content.
Animals and treatment
Eight-week old male KKAy mice were obtained from
Beijing HFK Bioscience Co., Ltd. (Beijing, China). Age
and sex-matched non-diabetic C57BL/6J mice were
obtained from Shanghai SLAC laboratory Animal Co.,
Ltd. (Shanghai, China).
Mice treated with XKA were based on our previous
study [16], and more measurements and analysis were
presented in this study. Briefly, all mice were housed
in an environmentally controlled room at 22 ± 2 °C
with a relative humidity of 55 ± 15 %, under a 12 h
light/dark cycle. The KKAy mice were fed a high-fat
diet as models of T2D [17], whereas C57BL/6J mice
were fed normal chow diet as non-diabetic controls.
All animals were allowed ad libitum access to solid
food and water. They were used in experiments after
2 weeks of acclimation. All experimental procedures were
approved by the Animal Ethic Review Committees of
Zhejiang University.
Ten-week old KKAy mice were randomly divided into
4 groups according to fasting blood glucose values.
Then, the KKAy mice were administered by oral gavage
once daily with distilled water, XKA (1.5 g/kg), XKA
(0.75 g/kg), or metformin (250 mg/kg), for a duration
of 32 days. At the same time, the non-diabetic controls
received distilled water.
During the experiment, body weight was monitored
regularly. Blood glucose values were determined regu-
larly for the non-fasting and fasting (after a 5 h fast)
mice using the One-Touch Ultra blood glucose meter
(Lifescan, CA, USA) by collecting blood from the tip
of the tail vein. After 32 days of drug administration,
blood samples were taken and mice were immediately
sacrificed by cervical dislocation in the fed state. The
liver, kidney, spleen, heart and adipose tissues were
collected and weighted. The livers from non-diabetic
controls, diabetic models and XKA (1.5 g/kg) treat-
ment groups were stored in liquid nitrogen for further
microarray experiment.
Oral glucose tolerance test
After 30 days of treatment, an oral glucose tolerance
test (OGTT) was performed. Briefly, after animals
fasted for 5 h, glucose at a dose of 2.0 g/kg was then
orally administered to the mice. The blood glucose
levels were measured before and 30, 60, 120 min after
glucose administration using a One-Touch Ultra blood
glucose meter. The results of the OGTT were also
expressed as area under the glycemia-versus-time
Fig. 2 Effect of XKA on cell viability of 3T3-L1 preadipocytes. All values are represented as means ± SD (n = 3)
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curve (AUC). The AUC during the OGTT was calcu-
lated via the following equation:
AUC mmol  h=Lð Þ ¼ 0:25  BG0 min þ 0:5
 BG30 min þ 0:75
 BG60 min þ 0:5
 BG120 min: ð1Þ
Blood sample analysis
After 32 days of treatment, blood samples were obtained
in the fasting state. Serum samples were separated from
the blood and stored at -20 °C until measurement.
Serum TG, TC, HDL-c and low-density lipoprotein chol-
esterol (LDL-c) measurements were carried out with a
Hitachi 7600 Automatic Analyzer using appropriate kits.
The atherogenic index [18] was calculated using the fol-
lowing equation:
Atherogenic index ¼ TC‐HDL‐cð Þ=HDL‐c ð2Þ
RNA extraction purification and quality assessment
The RNA extraction and quality evaluations were carried
out as described before [16].
Microarray experiment
Affymetrix mouse 430 2.0 chips were used. Whole
genome microarray analysis was performed using Affy-
metrix products as described in our previous study [16].
Five mice per group were used for the microarray exper-
iments. The dataset was deposited as CEL files to GEO
and the access number is GSE62087.
Fig. 3 Effect of XKA on adipocyte differentiation. Representative pictures
of preadipocyte (a) and differentiation induced cells with Oil Red O
staining at XKA concentrations of 0 (b), 500 (c), 250 (d), 125 (e) and 62.5
(f) μg/mL (Original magnification 100 ×). Oil Red O dye in lipid droplets
was eluted into isopropanol to determine the accumulation of lipid
(g). All values are represented as means ± SD (n= 3). *p< 0.05 vs. control
group, **p< 0.01 vs. control group
Fig. 4 Effect of XKA on TG and TC accumulation in 3T3-L1 cells. The
concentrations of XKA were both 500 μg/mL in (a) and (b). All values
are means ± SD (n = 3). *p < 0.05 vs. control group, **p < 0.01 vs.
control group
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Microarray data analysis
Raw data were analyzed in ArrayTrack 3.5.0 [19], a java-
based microarray analysis tool developed by the US FDA.
Global scaling normalization was performed with Median
Scaling Normalization using a target median value of 1000.
Reverse rate (RR) [15] was used to evaluate the effect of
XKA in reversing the changes of gene expression in dia-
betic models. It was calculated via the following equation:
RR ¼ Mi‐Tið Þ= Mi‐Nið Þ ð3Þ
In equation (3), Ni, Mi and Ti refer to the average expres-
sions of gene i in normal group, model group and XKA
treatment group, respectively.
The network recovery index (NRI) [20] was used to
quantitatively evaluate the network rebalance effect of
drug treatment in the unbalanced molecular network of
T2D. In our previous work, a T2D molecular network [21]
was constructed, which was used for the NRI evaluation in
this study. The process of NRI calculation was described
previously [20]. Briefly, the regulating score (RS) and the
ratio of recovery regulation (Rr) should be calculated first,
and then NRI could be obtained.
Firstly, RS was calculated to evaluate the influence












In equation (4), Em, Et and En refer to the expression
value of the diabetic model group, the drug treatment
Fig. 5 In vivo glucose levels down-regulation effect of XKA in KKAy mice. Fasting (a) and non-fasting (b) blood glucose was determined at indicated
time. All values are means ± SD (n = 10–11). *p < 0.05 vs. KKAy mice, **p < 0.01 vs. KKAy mice
Fig. 6 Effects of XKA on oral glucose tolerance test (OGTT). OGTT was carried out at day 30 (a), and the AUC of OGTT was calculated (b). All
values are means ± SD (n = 10–11). *p < 0.05 vs. KKAy mice, **p < 0.01 vs. KKAy mice
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group and the normal group, respectively. In this study,
nodes with RS (diabetic model) > 0.5 were considered as
upregulated nodes, while RS (diabetic model) <−0.33
were defined as downregulated ones.
Rr was calculated as the ratio of nodes with recovery



















In equation (5), RSi,m, RSi,t refer to the RS value of
node i in diabetic model group and drug treatment
group, respectively.
NRI was calculated as average Rr score of up-, down-
regulated nodes and all the nodes in the T2D network
by equation (6).
NRI ¼ mean Rrup; Rrdown; Rrtotalð Þ ð6Þ
In equation (6), Rrup, Rrdown and Rrtotal refer to the Rr
score of upregulated nodes, downregulated nodes and all
nodes, respectively.
Real-time quantitative RT-PCR
The microarray data was validated by real-time quantita-
tive RT-PCR. Total RNA (1 μg) was used for cDNA
synthesis, using QuantiTect Reverse Transcription Kit
(Qiagen) according to the manufacturer’s instructions.
PCR reactions were carried out using QuantiFast
SYBR Green PCR Kit (Qiagen) according to the manu-
facturer’s protocol in an Eppendorf realplex system
(Hamburg, Germany). Primer sequences are listed in
Additional file 1. Thermal cycling conditions were as
follows: 95 °C for 5 min followed by 40 cycles at 95 °C
for 10 s and 60 °C for 30 s. The relative expression level
for each gene was normalized to that of β-actin and
reported as mean relative changes (± SD) compared with
normal controls.
Statistical analysis
Data are expressed as mean ± SD. Significance analysis
was performed using one-way analysis of variance
(ANOVA) with Dunnett's post-hoc test for multiple
comparison analysis, and p < 0.05 was regarded as statis-
tically significant.
Results
Inhibition of 3T3-L1 cells differentiation by XKA
To determine the effects of XKA on 3T3-L1 cells dif-
ferentiation, confluent 3T3-L1 cells were treated with
different concentrations of XKA extracts. The anti-
adipogenic effect of XKA was investigated at concen-
trations with no effect on cell viability according to
MTT assay (Fig. 2). Following various treatments, Oil
Red O was used to stain the differentiated 3T3-L1
cells in 24-well plates (Fig. 3). Microscopic observa-
tion of cells with Oil Red O staining indicated that
Table 1 Effect of XKA on serum lipid profile in diabetic KKAy mice
C57BL/6J KKAy KKAy + XKA-H KKAy + XKA-L KKAy +MET
TG (mmol/L) 1.29 ± 0.17 2.03 ± 0.85# 1.41 ± 0.59* 1.65 ± 0.33 1.64 ± 0.56
TC (mmol/L) 2.33 ± 0.21 4.61 ± 1.01## 4.92 ± 1.65 4.44 ± 0.83 4.85 ± 0.97
HDL-c (mmol/L) 1.42 ± 0.16 2.75 ± 0.60## 3.42 ± 1.42 2.94 ± 0.70 3.21 ± 0.75
LDL-c (mmol/L) 0.408 ± 0.075 0.565 ± 0.121# 0.617 ± 0.169 0.513 ± 0.111 0.565 ± 0.087
TC/HDL-c 1.64 ± 0.07 1.68 ± 0.13 1.48 ± 0.17** 1.53 ± 0.14* 1.53 ± 0.15*
Atherogenic index 0.639 ± 0.066 0.685 ± 0.127 0.483 ± 0.167** 0.530 ± 0.145* 0.533 ± 0.146*
All values are means ± SD (n = 10–11)
#p < 0.05 vs. C57BL/6J mice
##p < 0.01 vs. C57BL/6J mice
*p < 0.05 vs. KKAy mice
**p < 0.01 vs. KKAy mice
Fig. 7 Effects of XKA on body weight in KKAy mice. All values are
means ± SD (n = 10–11)
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XKA reduced lipid accumulation in a dose-dependent
manner. This result was confirmed by quantitative
data derived from spectrophotometric measure of Oil
Red O-stained lipid droplets eluted by isopropanol,
which demonstrated that XKA effectively inhibited
adipocyte differentiation compared to control at con-
centrations of 500 and 250 μg/mL (p < 0.01, Fig. 3).
Compared to control, the intracellular TC and TG
contents of XKA treated 3T3-L1 cells were lowered by
41.3 % (p < 0.01) and 25.0 % (p < 0.05), respectively
(Fig. 4). Therefore, XKA treatment led to an inhibition
of 3T3-L1 adipocyte differentiation.
Effect of XKA on blood glucose levels in KKAy mice
To evaluate the effect of XKA on blood glucose levels, the
KKAy mice were treated with 0.75 g/kg XKA, 1.5 g/kg
XKA, 250 mg/kg metformin or distilled water for 32 days.
Blood glucose values of the diabetic model group
were significantly higher than those of the C57BL/6J
mice. The blood glucose attenuation effect of XKA
was dose-dependent. At the 4th week treatment with
1.5 g/kg XKA, the fasting and non-fasting blood glu-
cose levels of the KKAy mice decreased by 26.4 % (p
< 0.01) and 16.8 %, respectively (Fig. 5). In diabetic
KKAy mice, XKA at a dose of 1.5 g/kg showed simi-
lar treatment effects to that of metformin.
Effect of XKA on oral glucose tolerance in KKAy mice
In the present study, oral glucose tolerance tests were
performed in the mice after 30 days of treatment to
determine the whole-body insulin sensitivity. Com-
pared with the non-diabetic controls, the diabetic
model group exhibited a stronger hyperglycemic
response to oral glucose administration. Significant
differences in blood glucose levels over time were ob-
served for XKA (1.5 g/kg) and metformin 120 min
post glucose challenge, compared with vehicle-treated
KKAy mice (Fig. 6). Moreover, the AUC in the XKA
(1.5 g/kg) treated group decreased significantly
compared to the vehicle-treated group. In addition,
XKA improved the oral glucose tolerance in a dose-
dependent manner.
Effect of XKA on dyslipidemia in KKAy mice
To evaluate the effects of XKA on dyslipidemia, the levels
of TG, TC, HDL-c and LDL-c in KKAy mice were deter-
mined, as shown in Table 1. Compared to diabetic model
group, the serum lipid profile was improved to some extent
by XKA treatment in KKAy mice. XKA (1.5 g/kg) and
XKA (0.75 g/kg) could decrease serum TG level by 30.3 %
and 18.7 %, respectively. The level of serum HDL-c was
elevated by XKA (1.5 g/kg) by 24.5 %. TC-HDL-c ratio is
an independent predictors of coronary heart disease (CHD)
events [22]. In XKA (1.5 g/kg and 0.75 g/kg) treatment
groups, TC-HDL-c ratio of KKAy mice was significantly
lowered by 12.0 % and 9.2 %, respectively. The atherogenic
index, as a risk factor for coronary artery disease, was
significantly decreased by both doses of XKA.
Effect of XKA on body weight in KKAy mice
The effects of XKA on body weight changes were
observed in KKAy mice during the treatment period.
As shown in Fig. 7, the body weight of all mice in-
creased continuously during the first three weeks, and
it became stabilized in the fourth week.
Table 2 Effect of XKA on tissue weight in diabetic KKAy mice
C57BL/6J KKAy KKAy + XKA-H KKAy + XKA-L KKAy + MET
Liver (g) 1.03 ± 0.12 2.11 ± 0.35## 1.95 ± 0.62 1.82 ± 0.46 1.91 ± 0.30
Relative liver weight 0.042 ± 0.002 0.058 ± 0.007## 0.051 ± 0.011 0.049 ± 0.010 0.051 ± 0.007
Epidydimal fat pad (g) 0.23 ± 0.05 1.10 ± 0.23## 1.23 ± 0.22 1.29 ± 0.30 1.28 ± 0.38
Relative epidydimal fat weight 0.010 ± 0.002 0.030 ± 0.006## 0.033 ± 0.005 0.035 ± 0.008 0.034 ± 0.010
Perirenal fat (g) 0.05 ± 0.02 0.49 ± 0.14## 0.57 ± 0.19 0.58 ± 0.13 0.56 ± 0.16
Relative perirenal fat weight 0.002 ± 0.001 0.014 ± 0.004## 0.015 ± 0.004 0.016 ± 0.004 0.015 ± 0.004
Spleen (g) 0.07 ± 0.01 0.12 ± 0.04## 0.10 ± 0.02 0.10 ± 0.03 0.10 ± 0.01
Relative spleen weight 0.0027 ± 0.0004 0.0033 ± 0.0007# 0.0028 ± 0.0004 0.0026 ± 0.0007* 0.0026 ± 0.0003*
Kidney (g) 0.33 ± 0.04 0.47 ± 0.08## 0.44 ± 0.07 0.42 ± 0.04 0.42 ± 0.04
Relative kidney weight 0.014 ± 0.001 0.013 ± 0.001 0.012 ± 0.001 0.012 ± 0.001* 0.011 ± 0.001**
Heart (g) 0.13 ± 0.02 0.15 ± 0.03 0.15 ± 0.02 0.14 ± 0.01 0.15 ± 0.02
Relative heart weight 0.005 ± 0.001 0.004 ± 0.001## 0.004 ± 0.001 0.004 ± 0.000 0.004 ± 0.001
All values are means ± SD (n = 10–11)
#p < 0.05 vs. C57BL/6J mice
##p < 0.01 vs. C57BL/6J mice
*p < 0.05 vs. KKAy mice
**p < 0.01 vs. KKAy mice
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The body weight gain of diabetic model group was not
statistically different from that of the groups treated with
XKA or metformin. The body weight of C57BL/6J was
significantly lower than that of the diabetic ones.
Effect of XKA on tissue weight in KKAy mice
The liver/body weight ratio and spleen/body weight
ratio of the diabetic model was much greater than that
of the lean mice. However, the relative liver and spleen
Fig. 8 T2D network with reverse rate of XKA. This figure illustrates the reverse rate values of the nodes in the network, and the holistic reversal
effect of XKA could be seen intuitively in the T2D network. The color of the nodes in the network presented the reverse rate of the nodes with
the treatment of XKA. The network was visualized by Cytoscape
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weight decreased after the XKA treatment (Table 2).
Especially, the relative spleen weight of the XKA-L
(0.75 g/kg) treatment group showed statistical signifi-
cance (p < 0.05), while the metformin treatment group
showed a similar effect as XKA-L. The relative epidydi-
mal fat and heart weight between the diabetic model
and the treatment group didn’t exhibit statistical sig-
nificant difference.
T2D disease network recovery effects of XKA
The RR values were mapped to the nodes in the T2D
network constructed previously [21], as shown in Fig. 8.
The network was visualized by Cytoscape [23]. The color
of the nodes in the network presented the reverse rate of
the nodes with the treatment of XKA. Therefore, the
holistic reversal effect of XKA was displayed intuitively
in the T2D network.
As shown in Table 3, the number of up- and down-
regulated nodes by T2D was 71 and 91 in the T2D
network. In total, 93.0 % (66/71) of up-regulated genes
and 80.2 % (73/91) of down-regulated genes were recov-
ered, while the 68.0 % (568/835) of all genes in the T2D
network were recovered. The Rr scores of up- and
down-regulated nodes showed higher degree of recovery
regulation, which indicated that XKA exhibited more
beneficial effects on the significantly perturbed nodes in
T2D. As mentioned above, Rrup, Rrdown and Rrtotal were
0.930, 0.802 and 0.680, respectively. Therefore, the NRI
of XKA was 0.804 according to equation (6). The NRIs
of the T2D-related pathways summarized in T2D@ZJU
(http://tcm.zju.edu.cn/t2d) were also calculated, which
were presented in Additional file 2.
Verification of microarray gene expression data by real-
time quantitative RT-PCR
The expression levels of highly reversed transcripts
were confirmed by real-time quantitative RT-PCR
(Fig. 9). These genes include glycerol phosphate de-
hydrogenase 2, mitochondrial (Gpd2), fibroblast growth
factor 1 (Fgf1) and guanine nucleotide binding protein
(G protein), alpha inhibiting 1 (Gnai1). The real-time
quantitative RT-PCR expression levels were found to be
consistent among biological replicates and in similar
patterns with the microarray data.
Discussion
T2D is one of the most prevalent and serious metabolic
diseases in the world characterized by disorders of glu-
cose and lipid metabolism. TCM is receiving more
attention all over the world for its outstanding efficacy
as multi-target drugs with less frequent adverse effects.
Unlike the common antidiabetic chemical drugs aimed
at a specific single target, TCM attempted to restore
the balance of a perturbed molecular disease network
with integrated effects of multi-components upon
multi-targets and multi-pathways. The evaluation of the
antidiabetic chemical drugs is relatively simple, e.g. blood
glucose levels should examined for anti-hyperglycemia
drugs, while the blood triglyceride and total cholesterol
levels should be examined to evaluate the efficacy of anti-
hyperlipidemia ones. However, a single index or bio-
marker could barely reflect the holistic treatments and the
integrated effects of TCM.
In this study, XKA was investigated for the therapeutic
effects in 3T3-L1 cells and KKAy mice with both con-
ventional methods and holistic ones. In vitro, XKA
inhibited adipogenic differentiation, lowered the intra-
cellular TC and TG contents in 3T3-L1 cells. In KKAy
mice, XKA administration did not show any significant
effect on body weight. After the treatment, average
blood glucose levels of XKA treated groups were lower
than vehicle control. The blood triglyceride levels of
Table 3 The regulation of the T2D network by XKA
Number of
reversed nodes
Number of nodes Rr
Nodes up-regulated 66 71 0.930
Nodes down-regulated 73 91 0.802
Total nodes 568 835 0.680
Fig. 9 Validation of microarray gene expression data by real-time quantitative RT-PCR. Black bars indicate the relative gene expression from microarray
data, while gray bars indicate that from real-time quantitative RT-PCR. (a) Gpd2, (b) Fgf1, (c) Gnai1. All values are means ± SD (n = 5). #p < 0.05 vs.
C57BL/6J mice, ##p < 0.01 vs. C57BL/6J mice, *p < 0.05 vs. KKAy mice, **p < 0.01 vs. KKAy mice
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XKA treated groups were also lower than the vehicle
control, while the HDL-c levels of XKA treated groups
were higher. The TC-HDL-c ratio and the atherogenic
index of XKA treated KKAy mice were both signifi-
cantly improved. Therefore, XKA exhibited the effects
of improvement in the disorders of glucose and lipid
metabolism. In the OGTT, the KKAy mice given XKA
(1.5 g/kg body weight) showed significant improvement
in insulin sensitivity compared to vehicle control. This
indicates that XKA could improve the insulin sensitivity
in diabetic animal model. Taken together, treatment
with XKA exhibited the effects in attenuating the disor-
ders in glucose and lipid metabolism and alleviating the
insulin resistance, both of which were important char-
acteristics of T2D. Phenolic acids derived from Salviae
miltiorrhizae radix et rhizoma, xanthones derived from
Anemarrhenae rhizoma, iridoids derived from Rehman-
niae radix, triterpenoid saponins from Ginseng radix et
rhizoma and alkaloids from Coptidis rhizoma might be
the principal anti-diabetic components in XKA based
upon network analysis [16].
TCMs, like many other herbal medicines, exert inte-
grated effects through multi-components. A few holis-
tic and integrated approaches have been developed to
discover the effective substances, as well as the efficacy
and safety of TCMs [24, 25]. In this study, a strategy
integrating network pharmacology analysis technology
and ‘omics’ data was adopted. As a key tissue to regu-
late the metabolism related pathways, livers of these
mice were collected for further systems biology research.
In our previous study, a T2D associated molecular
network was constructed by organizing T2D-related path-
ways in several well-known pathway databases. RR was
used to evaluate the effects of XKA in reversing the
changes of gene expression in diabetic models. The RR
values were mapped to the nodes in the T2D network, as
shown in Fig. 8. This result implied that XKA has a
reverse effect on T2D, indicating treatment efficacy of
XKA from a network perspective.
In order to quantitatively evaluate the efficacy of XKA,
several index associated with network recovery were
calculated. Rrup, Rrdown and Rrtotal were 0.930, 0.802 and
0.680, respectively. The values of Rrup and Rrdown were
both higher than that of Rrtotal, which implicated that
XKA exhibited greater reverse effects in the seriously
deviated nodes in disease state. In this study, NRI was
used to quantitatively evaluate the network rebalance
effect of drug treatment in the unbalanced molecular
network of T2D. The NRI was a value between 0 and 1,
and a higher NRI represented a better treatment efficacy
of drug in treating T2D. The NRI of XKA was calculated
to be 0.804, which indicated a well-performed network
rebalance effect of XKA. The NRIs of the T2D-related
pathways were useful index suggesting the XKA’s probable
mechanisms of action. The top 2 NRIs of these pathways
derived from “Glycolysis and Gluconeogenesis” pathway
and “Fatty acid biosynthesis and metabolism” pathway,
with NRIs of 0.947 and 0.938, respectively. It indicated
that attenuating the disorders in glucose and lipid metab-
olism might be XKA’s major antidiabetic mechanisms.
The NRI of “Insulin Signaling” pathway was 0.897, which
meant that XKA might also alleviate insulin resistance.
These results were consistent with the phenotype indexes
in cell and animal as mentioned above.
Conclusion
In conclusion, XKA, as an example of TCM in treating
T2D, was investigated for its therapeutic effects in 3T3-
L1 cells and KKAy mice with both conventional and
holistic omics methods. In 3T3-L1 cells, XKA inhibited
adipogenic differentiation, lowered the intracellular TC
and TG contents. In KKAy mice, XKA reduced blood
glucose, serum triglyceride, increased serum HDL-c,
lowered the atherogenic index and improved insulin re-
sistance. Furthermore, the microarray data of liver was
integrated with the molecular T2D network to evaluate
the efficacy of XKA at a systems level. The results indi-
cated an effective therapy of XKA by reversing the mo-
lecular T2D disease network from a perturbed state.
Integrating the conventional and the holistic omics ap-
proach, the antidiabetic effect of XKA was evaluated
more comprehensively to provide both phenotypic evi-
dence and underlying action mechanisms for the clin-
ical use of XKA treating T2D.
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